DAHUA-TECHNOLOGY
7.9.2021 15:47:05 CEST | Business Wire | Press release
Dahua Technology, a world leading video-centric smart IoT solution and service provider, has launched its upgraded Three-in-One Camera series – the TiOC 2.0 . It is equipped with intelligent features that can help ease your monitoring operation and customize your alarm system based on your actual needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005426/en/
Smart Dual Illuminators
The TiOC 2.0 features Smart Illumination Mode (default mode) that turns on the white light when a target is detected (PTZ camera tracks the target). The active alarm (siren and red & blue light) will be triggered if the target enters the rule area. When the target leaves the monitored area, the white light turns off (PTZ camera goes back to preset) and the IR illuminator turns back on, which helps reduce light pollution at night.
VoiceCatcher Technology
The Dahua VoiceCatcher technology adopts a high-sensitivity dual mic array – a newly designed audio acquisition circuit that can intercept external circuit interference. With Dahua’s self-developed noise reduction algorithm and high-performance SOC, it increases the camera’s audio pick-up distance by 7 meters (based on standard laboratory environment). Combined with built-in speaker, VoiceCatcher greatly enhances the device’s Two-way Talk function.
Better Image
The OPC (Optical Path Compensation) technology enables TiOC 2.0 cameras to correct the angle of refraction of different light rays, allowing Dahua IPCs to output brighter and clearer black & white images with F1.0 large aperture lens. It increases the light input by 1.96 times and 2.56 times compared with F1.4 and F1.6 respectively. Also, the upgraded hardware and software provide a smooth visual experience (4K @25/30 fps) even with enabled AI.
Other Features
TiOC 2.0 supports configuration of alarm-in ports directly on the webpage interface. Aside from Perimeter Protection , SMD 3.0 and Active Deterrence , this series is also equipped with Auto Tracking 3.0 (via PTZ camera) that utilizes a deep fusion of intelligent and focusing algorithms (PFA 3.0), providing longer tracking distance of up to 870 meters.
Conclusion
Overall, the upgraded Dahua TiOC 2.0 offers innovative features that allow users to customize their monitoring systems. With new features such as Smart Dual Illuminators, VoiceCatcher technology, OPC, and Auto Tracking 3.0, this series embodies Dahua Technology’s dedication to “Innovation, Quality and Service” in order to serve its partners and customers around the world.
Note:
Full-color 2.0 & TiOC 2.0 Online Launch Conference
September 14, 2021 (17:00-18:00 Beijing Time)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005426/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom